References

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy

10.2147/btt.s114530 · 2019 · External reference

Accelerating drug development for neuroblastoma: Consensus statement from the third neuroblastoma drug development strategy forum

10.1002/pbc.31831 · 2025 · External reference

Anti-GD2 immunotherapy for neuroblastoma

10.1080/14737140.2017.1364995 · 2017 · External reference

Unresolved reference

External reference

High-risk neuroblastoma challenges and opportunities for antibody-based cellular immunotherapy

10.3390/jcm13164765 · 2024 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Efficacy and safety of anti-GD2 immunotherapy with dinutuximab beta in the treatment of relapsed/refractory high-risk neuroblastoma

10.1007/s11523-025-01155-3 · 2025 · External reference

Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 study (HR-NBL1)

10.3390/cancers12020309 · 2020 · External reference

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons

10.3389/fonc.2025.1736165 · 2026 · External reference

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

10.1056/nejmoa0911123 · 2010 · External reference

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

10.1016/s1470-2045(17)30355-8 · 2017 · External reference

Dinutuximab beta added to temozolomide-based chemotherapy for children with relapsed and refractory neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II trial

10.1200/jco-25-01868 · 2026 · External reference

Dinutuximab beta maintenance therapy in patients with high-risk neuroblastoma in first-line and refractory/relapsed settings-real-world data

10.3390/jcm12165252 · 2023 · External reference

Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter

10.1016/j.ejca.2024.114001 · 2024 · External reference

Early salvage chemo-immunotherapy with irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) for patients with primary refractory high-risk neuroblastoma provide the best chance for long-term outcomes

10.3390/cancers15194837 · 2023 · External reference

Progression-free survival and patterns of response in patients with relapsed high-risk neuroblastoma treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor

10.1200/jco.22.01273 · 2023 · External reference

The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial

10.1038/s41467-025-56619-x · 2025 · External reference

Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission

10.1002/ijc.70329 · 2026 · External reference

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience

10.3389/fonc.2022.1041443 · 2022 · External reference

Assessment of chemo-immunotherapy regimens in patients with refractory or relapsed neuroblastoma: a systematic review with meta-analysis of critical oncological outcomes

10.3390/jcm14030934 · 2025 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

10.1016/s1470-2045(18)30578-3 · 2018 · External reference

Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial

10.1200/jco.2019.37.15_suppl.10014 · 2019 · External reference

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

10.1200/jco.2007.13.8925 · 2009 · External reference

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study

10.1038/s41416-023-02457-x · 2023 · External reference

To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma

10.1002/pbc.29663 · 2022 · External reference

GM-CSF: A double-edged sword in cancer immunotherapy

10.3389/fimmu.2022.901277 · 2022 · External reference

GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma

10.1002/ijc.34815 · 2024 · External reference

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment

10.1136/jitc-2020-002259 · 2021 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · 2021 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

10.1136/bmj.i4919 · 2016 · External reference

A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China

10.1186/s12887-025-05568-x · 2025 · External reference

Extended cycles of anti-GD2 antibody dinutuximab beta treatment combined with chemotherapy in patients with relapsed or refractory neuroblastoma: a retrospective study

10.3892/ol.2025.15438 · 2026 · External reference

Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial

10.1186/s13045-025-01770-7 · 2025 · External reference

A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission

10.1002/ijc.70374 · 2026 · External reference

Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin ± chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China

10.3389/fonc.2026.1765578 · 2026 · External reference

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

10.1200/jco.2011.41.3807 · 2012 · External reference

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

10.1002/(sici)1097-0142(19970715)80:2<317::aid-cncr21>3.0.co;2-w · 1997 · External reference

GD2-targeting therapy: a comparative analysis of approaches and promising directions

10.3389/fimmu.2024.1371345 · 2024 · External reference

Affinity affects the functional potency of anti-GD2 antibodies by target-mediated drug disposition

10.3390/cancers17152510 · 2025 · External reference

Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor

10.1200/jco.2011.37.6236 · 2012 · External reference

Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types

10.1038/emm.2016.64 · 2016 · External reference